Pleural Mesotheliomas Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Pleural Mesothelioma

IndicationStatusPhase
DBCOND0029910 (Pleural Mesotheliomas)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02707666A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural MesotheliomaTreatment